Sexually Transmitted Diseases

The recent death of an infant in Iowa who got meningitis following exposure to the herpes simplex virus serves as a grim reminder of how dangerous the virus can be for newborns.

Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).

New research on Zika, cases of swine flu infections, parallels between Zika and HIV, a new warning sign of HIV infection, and an increase in cyclospora cayetanensis infections in United States make up the top 5 articles this week.

Researchers from LSU Health New Orleans School of Public Health finds that heterosexuals at-risk for HIV would use home-based testing kits and seek treatment if they receive a positive result.

The risk of mortality is elevated in HIV-positive individuals who have detectable levels of virus 6 months after beginning antiretroviral therapy.

Despite the progress that has been made, more research is needed on cancer prevention, hepatitis B, and human papillomavirus vaccines.

Parallels between the recent Zika epidemic in Brazil and the HIV pandemic in the 1980s, stress the importance of improving responses to public health crises.

Florida reports first case of sexually-transmitted Zika of 2017, while funds continue to be released for new research efforts against the virus and tests to aid in rapid diagnosis.

Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.

Researchers report a case of undiagnosed HIV infection that first presented as necrotizing ulcerative stomatitis.

A recent study takes a closer look at statin use in HIV-positive patients who are taking protease inhibitors.

New HIV drugs, vaccine regulations in France, correlations between intestinal viruses & type 1 diabetes, the susceptibility of Florida mosquitoes to transmit chikungunya, and an evaluation of the risk of hepatitis B reactivation in veterans on direct-acting antiviral therapy make up our Top 5 articles for the week of July 30, 2017.

A recent study showed that most migrants to European countries acquired their HIV infections in their host countries, particularly those from Latin America and the Caribbean.

Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.

Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.

The relationship between temperature and incidence of surgical site infections, progress towards an HIV vaccine, the cleanliness of your stethoscope, an explanation on how infection rates at Stanford Hospital are a canary in a coal mine, and an interactive visual map that depicts the HIV epidemic in the United States, make up the Top 5 news articles for the month of July 2017.

Introducing HIV screening in primary care offices has the potential to save lives and decrease the costs associated with treatment by increasing rates of early diagnosis.

In a recent editorial, Matthew Barnhart MD, MPH, medical officer for the US Agency for International Development (USAID) explored 5 new HIV drugs that are in the pipeline.

Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.

Pedro Cahn, MD, explains the new formulation of raltegravir HD.

Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.

Nader Pourhassan, PHD, president and chief executive officer of CytoDyn, the biotechnology company that acquired PRO 140, offers insight into the antibody as treatment for HIV.

Lynne Mofenson, MD, shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.

Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.

Due to concerns that the use of PrEP might hinder clinicians from detecting HIV in infected individuals or lead to the development of resistant strains of HIV, scientists studied how PrEP affects seroconversion after HIV is acquired.